QS Investors LLC lowered its stake in Enanta Pharmaceuticals (NASDAQ:ENTA) by 0.9% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 75,704 shares of the biotechnology company’s stock after selling 705 shares during the quarter. QS Investors LLC owned about 0.40% of Enanta Pharmaceuticals worth $4,442,000 as of its most recent SEC filing.
A number of other hedge funds also recently made changes to their positions in the business. Financial Gravity Companies Inc. bought a new stake in shares of Enanta Pharmaceuticals in the 4th quarter worth about $181,000. East Coast Asset Management LLC. bought a new stake in shares of Enanta Pharmaceuticals in the 4th quarter worth about $218,000. LS Investment Advisors LLC increased its holdings in shares of Enanta Pharmaceuticals by 56.8% in the 4th quarter. LS Investment Advisors LLC now owns 3,714 shares of the biotechnology company’s stock worth $218,000 after buying an additional 1,345 shares during the last quarter. Campbell & CO Investment Adviser LLC bought a new stake in shares of Enanta Pharmaceuticals in the 3rd quarter worth about $220,000. Finally, Hartland & Co. LLC bought a new stake in shares of Enanta Pharmaceuticals in the 3rd quarter worth about $237,000. Institutional investors and hedge funds own 73.25% of the company’s stock.
NASDAQ:ENTA traded down $3.52 during mid-day trading on Friday, hitting $81.85. 148,577 shares of the stock traded hands, compared to its average volume of 181,238. The company has a market capitalization of $1,635.75, a price-to-earnings ratio of 89.95 and a beta of 1.07. Enanta Pharmaceuticals has a 52 week low of $29.23 and a 52 week high of $95.91.
Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings results on Wednesday, February 7th. The biotechnology company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.05 by $0.73. The company had revenue of $38.11 million for the quarter, compared to the consensus estimate of $27.26 million. Enanta Pharmaceuticals had a net margin of 26.35% and a return on equity of 13.33%. analysts predict that Enanta Pharmaceuticals will post 0.86 earnings per share for the current fiscal year.
A number of research firms have recently weighed in on ENTA. Royal Bank of Canada restated a “hold” rating and issued a $80.00 target price on shares of Enanta Pharmaceuticals in a report on Wednesday. ValuEngine upgraded shares of Enanta Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Monday, April 2nd. BidaskClub upgraded shares of Enanta Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Wednesday, March 14th. JPMorgan Chase downgraded shares of Enanta Pharmaceuticals from an “overweight” rating to a “neutral” rating in a report on Thursday, February 8th. Finally, Zacks Investment Research upgraded shares of Enanta Pharmaceuticals from a “hold” rating to a “buy” rating and set a $82.00 price target on the stock in a report on Monday, February 12th. Three equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and two have given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $57.80.
In other Enanta Pharmaceuticals news, Treasurer Paul J. Mellett sold 9,000 shares of the company’s stock in a transaction dated Monday, March 19th. The shares were sold at an average price of $86.48, for a total value of $778,320.00. Following the transaction, the treasurer now directly owns 96,458 shares in the company, valued at approximately $8,341,687.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 10.56% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Enanta Pharmaceuticals (ENTA) Shares Sold by QS Investors LLC” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark law. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/07/enanta-pharmaceuticals-inc-enta-shares-sold-by-qs-investors-llc.html.
About Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company's research and development focuses on disease targets: hepatitis B virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and respiratory syncytial virus.
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.